Logo

Ipsen's Cabometyx + Opdivo Receive EC's Approval as a 1L Treatment for Patients with Advanced Renal Cell Carcinoma

Share this

Ipsen's Cabometyx + Opdivo Receive EC's Approval as a 1L Treatment for Patients with Advanced Renal Cell Carcinoma

Shots:

  • The approval is based on P-III CheckMate -9ER trial involves assessing Cabometyx + Opdivo vs sunitinib in 651 patients with previously untreated advanced/m-RCC
  • The results demonstrated significant improvement across all efficacy EPs. The trial met its 1EPs i.e. showed doubled mPFS (16.6 vs 8.3mos.); ORR (55.7% vs. 27.1%); CR (8.0% vs 4.6%); OS (40% reduction in risk of death)- improvement in DCR with a lower rate of discontinuation- consistent efficacy benefits observed across key subgroups of patients and was well tolerated
  • The approval allows for the marketing of combination regimen in all 27 member states of the EU- Norway- Liechtenstein- and Iceland

  Ref: Business Wire | Image: Business Wire

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions